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Abstract

FOLATE CONJUGATED DENDRIMERS FOR TARGETED ANTICANCER
THERAPY

By Shannon Christine Andrews, Bachelor of Science
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University School of Medicine.

Virginia Commonwealth University, 2014
Major Director: W. Andrew Yeudall
ASSOCIATE PROFESSOR, DEPT OF ORAL & CRANIOFACIAL MOLECULAR
BIOLOGY, & DIRECTOR OF BASIC DENTAL SCIENCE EDUCATION, VCU

Anticancer therapeutics are often limited to suboptimal doses due to their lack of
selectivity for tumor cells and resultant damage to healthy tissue. These limitations
motivated researchers to develop tumor-specific delivery systems for improved therapeutic
efficacy and reduced unintended cytotoxicity. Polyamidoamine dendrimers offer an ideal
platform for designing targeted therapeutics with tunable characteristics that optimize

pharmacokinetic behavior and targeting specificity1. Ligand conjugation to dendrimer
provides the biochemical interaction necessary to activate tumor-specific receptors for
receptor-mediated endocytosis and effective internalization of polyplexes2. Tumor-specific
receptors overexpressed in carcinomas, like folate receptor-alpha (FOLRα), are targeted by
ligand-conjugated dendrimer to allow enhanced internalization of dendrimer and its
therapeutic cargo. We examined the cellular trafficking dynamics and potential of folateconjugated dendrimer for nucleic acid delivery in vitro. Results show folate-conjugation to
G4 PAMAM dendrimer (G4FA) confers enhanced uptake in FOLRα-positive tumor cells.
Cells internalize G4FA in a receptor-dependent manner with specificity for FOLRαpositive tumor cells.

1. Introduction

1.1 Cancer Prevalence and Tumor Development
According to the American Cancer Society, one half of all men and one third of all
women in the US will develop cancer during their lifetime. Cancer is a common term for
over 100 disease types, marked by abnormal cellular growth, malignant behavior, tumor
development, and eventually invasion and metastasis. It is among the leading causes of
death worldwide, claiming over 8.2 million lives in 2012 alone25. Although incidence is
high, overall cancer death rates are decreasing in the United States according to the
‘Annual Report to the Nation on Cancer Status’, conducted by a collaboration of the
American Cancer Society, the Centers for Disease Control and Prevention (CDC), the
National Cancer Institute (NCI), and the American Association of Central Cancer
Registries (NAACCR)3. The decline in overall cancer morbidity reflects progress in cancer
control and prevention, made possible through enhanced ability for early detection and
improved treatment options. Uncovering the human genome allowed discovery of cellular
and molecular mechanisms driven by human diseases. As the complex intricacies of
human disease states are unraveled, in parallel with biotechnological advances, opportunity
arises to improve diagnostics, prevention, and treatment options.
Carcinogenesis is a complex, multistep process involving numerous cellular
physiological systems2. Cells become cancerous when genetic mutations accumulate and
cause changes in normal cell behavior2. Genetic mutations of oncogenes and tumor
1

suppressor genes may result in uncontrolled cellular proliferation, amplified genomic
disorganization, tumor development, and malignancy4. The inherent complexity of cancer,
in its many varieties, implies a multifaceted, individualized treatment plan based on tumor
type.

1.2 Gliomas
Of particular interest to this paper is the treatment of gliomas, which have a
particularly dismal prognosis due to the disease state’s highly invasive nature. Gliomas
account for more than 70% of all brain tumors, including gliomas of astrocytic,
oligodendroglial, and ependymal origin5,6. Glioblastoma multiforme (GBM) is the most
malignant and most frequent glioma, accounting for 65% of gliomas5,6. Less than 3% of
GBM patients are still alive five years post-diagnosis6. This poor prognosis reflects a major
challenge associated with treatment of central nervous system (CNS) disease states.
Disorders of the CNS possess peripheral barriers, like the blood-brain barrier (BBB),
making it nearly impossible to penetrate with therapeutics. Approximately 98% of smallmolecule drugs and all large molecule drugs fail to cross the BBB, aside from a few natural
peptides and proteins, like insulin1. Therefore, it is essential to find ways to improve
delivery of therapeutics to CNS in order to diminish the poor prognosis associated with
such lethal disease states.
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1.3 Anticancer Therapeutic Limitations and Potential Solutions
Currently, cancer treatment is based on clinical staging determined by morphologic
diagnostics and therapeutic methods are limited to surgery, radiation, and
chemotherapeutics2. These conventional methods aim to halt tumor progression, either by
surgical removal or with ionizing radiation and/or chemically based chemotherapeutics
which kill tumor cells through dramatic disruption of physiological pathways.
Chemotherapeutics target components of cell cycle regulation active in proliferative cells
to effectively arrest cellular growth and activate cell death pathways. This method
effectively targets and destroys highly proliferative tumor cells, but it also damages healthy
tissue that is proliferative under normal circumstances, like myelogenic or gastrointestinal
cells, for example. This off target tissue damage gives rise to the side effects traditionally
associated with anticancer therapeutics, including myelo- and immunosuppression, fatigue,
alopecia, etc. and limits the use and efficacy of these drugs.
Anticancer therapeutics are often limited to suboptimal doses due to their lack of
selectivity for tumor cells and resultant damage to healthy tissue. Dose limitation leads to
inadequate drug concentrations at the tumor site, development of drug resistance, and
treatment failure2,7. These limitations associated with standard treatment options have
motivated researchers to develop targeting mechanisms intended to decrease off-target side
effects and improve therapeutic efficacy. The central objective of targeted therapy is to
direct therapeutics in sufficient quantities to the appropriate location.

3

1.4 Nanomedicine in Targeted Anticancer Therapeutics
The biomedical application of nanotechnology, i.e. nanomedicine, allows for
incredible innovation in health care research to design and engineer highly advanced nanoscale devices that operate at the cellular and molecular level—precisely where many
disease processes generate and perpetuate2. Nano-scale delivery systems, i.e. nanocarriers,
including liposomes, nanoparticles, polymeric micelles, dendrimers, linear polymers,
nanogels, etc. have received great attention in the development of targeted therapeutics due
to their multifunctional nature and molecular level of action2. Their use as synthetic vectors
for the delivery of gene therapy, imaging agents, antimicrobials, and chemotherapeutics
has great potential to improve diagnostics and treatment of human disease processes8.
Polymer- and nanoparticle-based delivery systems have been extensively reviewed and
employed for medical diagnostics, imaging, and treatment9. Specific design of nanocarrier
size, composition, solubility, electric charge, and chemical structure facilitates the delivery
system’s capabilities for specific use. These tunable characteristics can be selected for
specific design in personalized treatment.
Recent approaches in anticancer therapy aim at enhancing vector specificity to
improve therapeutic efficacy and reduce unintended cytotoxicity7. Nanoparticles can be
targeted to specific sites via simple surface additions which provide the biochemical
interaction with receptors expressed on target cells2. Tumor-specific molecular markers are
targeted in order to direct therapy to tumor cells, and effectively bypass normal cells10.
Research shows that the addition of a tumor-targeting mechanism, regardless of
nanocarrier type, enhances internalization and therapeutic efficacy of the delivery system9.
4

Folate receptor-alpha (FOLRα), a GPI anchored glycoprotein, is an attractive target for
ligand-directed therapeutics due to its frequent overexpression in a variety of malignancies
and little to no measurable expression in normal tissue11. Dendrimers, a class of
macromolecules with highly branched 3D structure, are ideal nanocarriers for targeted
delivery due to their low polydispersity and multi-functionality12. Their highly branched
three-dimensional structure provides an ideal platform for an array of surface
modifications designed to render efficient, biocompatible molecules for targeted therapy.
We hypothesize that folic acid utilized as a targeting ligand will enhance dendrimer
specificity and uptake in FOLRα-positive tumor cells.

1.5 Dendrimers
Dendrimers are a unique class of macromolecules characterized by a compactly
layered, tree-like architecture with multiple active terminal groups centralized around an
initiator core12. They are composed of individual dendrons that radiate from a central core;
each layer of branching unit constitutes one complete generation (G), identified by
number13. A series of controlled chemical additions produces highly organized polymers
with consistent, incremental increase in size, molecular weight, and number of surface
groups with increase in generation number13. Commercialization of PAMAM dendrimers
by Dendritech (Midland, MI) has allowed for their extensive use in nano-medical studies;
their unparalleled properties over traditional polymers have placed them at the forefront of
this research12. As delivery systems, dendrimers possess several advantageous
characteristics over other nanocarriers. These include (1) multifunctionality and targeting
5

ability, (2) enhanced pharmacokinetic behavior, (3) enhanced stability, solubility, and
permeability of drugs, (4) improved delivery efficiency, and (5) reduced side effects by
targeted delivery1.
Of particular interest to our studies are full generation four (G4) polyamidoamine
(PAMAM) dendrimers, which possess 64 primary amine terminal ends on their surface. A
full generation PAMAM dendrimer is polycationic, expressing primary amine on the
molecule’s surface, whereas a half-generation PAMAM dendrimer is polyanionic,
expressing carboxylic acids on the surface1. Numerous active terminal ends present on
PAMAM dendrimer surfaces provide an ideal, versatile platform for design of highly
specialized nanodevices with high loading capacity. Functional moieties currently under
investigation in association with dendrimer-based delivery systems include genes,
antisense oligonucleotides, peptides, low-molecular weight drugs and/or imaging agents,
among others12.

6

Figure 1. Generation Four Polyamidoamine Dendrimer. Schematic representation of
the structure of generation four PAMAM dendrimers. Abbreviations: G=generation;
Z=surface group for host-guest interactions and functionalization. Adapted from reference
1.1

7

Dendrimer-based delivery systems are capable of facilitating transport across
cellular membranes and/or various biological barriers that often pose an issue with
conventional delivery methods. Surface groups and molecular mass determine cellular
entry dynamics of dendrimer-based delivery systems. Amine-terminated (cationic)
dendrimers can efficiently complex with nucleic acids to form polyplexes that
subsequently interact with negatively charged cell surface groups12,14. Tertiary amines
present in the dendrimer branches provide high buffering capacity once polyplexes are
internalized to endosomal vesicles. The dendrimer acts as a “proton sponge,” wherein the
amines enable adsorbtion of protons released from ATPase, causing osmotic swelling,
effective endosomal escape, and release of polyplex into the cytoplasm1,12,14. Thus, the
association of DNA with dendrimer allows efficient internalization of DNA; suggesting a
viable approach for gene therapy and nucleic acid delivery, among several other potential
pharmaceutical and biomedical applications of dendrimer-based delivery systems. Several
studies suggest that favorable drug pharmacokinetics and high efficacy have been achieved
using dendrimer nanocarriers1.
Recent approaches aim at designing nanocarriers that possess specificity for
diseased tissue in order to improve therapeutic efficacy and reduce off-target side effects.
Active site-specific targeting of nanocarriers can be achieved by exploiting ligand-receptor
relationships that induce receptor-mediated endocytosis of polyplexes. Receptors
specifically overexpressed in diseased tissue, with little or no expression in normal tissue,
provide a tumor-specific target to direct therapeutics. Ligand for the targeted receptor is
conjugated to the nanocarrier surface to provide the biochemical interaction required to
8

activate the receptor and effectively internalize the dendrimer and its attached cargo15.
Previous work in our lab has explored the use of EGF-conjugated dendrimers for receptormediated endocytosis through the EGFR receptor, which is overexpressed in many
carcinomas. Results showed a 10-fold increase in gene delivery efficiency using the EGFconjugated dendrimer as compared to dendrimer without ligand conjugation14. Exploration
of similar pathways of receptor-mediated endocytosis merits further study in the design of
targeted therapeutics to engineer efficient, biocompatible vectors with ideal biodistribution
and pharmacokinetic behavior.

1.6 Folic Acid and FOLRα
Folic acid (FA) is an essential vitamin, provided by diet, that is naturally used in its
reduced and/or polyglutamated forms in DNA biosynthesis and methylation16. The major
route for folate acquisition in non-malignant cells is through the reduced folate carrier
(RFC). This ubiquitously expressed anion channel has relatively low folate-binding affinity
(Km=1-10 µM) and will not internalize folate-conjugates17. Because folate is essential for
the biosynthesis of nucleotide bases, it is consumed in elevated quantities in highly
proliferative cells. To support their high folate demand, tumor cells frequently up-regulate
expression of folate receptor-alpha (FOLRα; FOLR1), a GPI-anchored glycoprotein with
very high affinity for folic acid (KD~10-10 M)18.
Among tumor targets/markers, FOLRα has many advantages for application in
targeted therapeutics: (1) it binds folate, which is amenable to chemical conjugation with
other molecules without affecting binding affinity19, (2) FOLRα effectively internalizes
9

receptor-bound folate conjugates20 (3) FOLRα expression is only found in measurable
quantities in tumor cells and those involved in embryonic development (placenta, neural
tubes) and folate resorption (kidney)17. High affinity of receptor for ligand-conjugates
allows for administration of therapeutics at lower, less toxic concentrations, while still
saturating available receptors to achieve the appropriate clinical response21. FOLRα is
further identified as tumor-specific because its limited expression in normal tissue is
confined to the apical surface of polarized epithelia19. Therefore, FOLRα expressed in
normal tissue is unable to access intravenous FOLRα-directed therapeutics. However,
upon malignant transformation, cell polarity is often lost in diseased epithelia and FOLRα
becomes accessible to targeted drugs in circulation11. This dual mechanism for tumorspecificity has nominated the receptor’s natural ligand, folic acid, as an attractive targeting
ligand for therapies directed at FOLRα-positive malignancies11. Furthermore, folate is
stable, small in size, it is compatible with a variety of solvents, and has high binding
affinity for FOLRα, even when conjugated to other molecules (KD~10-10 M)11.
Several folate-conjugated nanoparticles are under investigation for targeted drug
delivery and/or imaging; including metallic nanoparticles, micelles, mesoporous silica,
liposomes, dendrimers, and nanotubes, among others15. Folate conjugates have
successfully delivered imaging and therapeutic agents in malignant cells in both animal
tumor models and human cancer patients, with preferential uptake seen in FOLRα+
cells11,15,20. Studies show folate-conjugated delivery systems exert low toxicity and show
increased efficacy and pharmacokinetic behavior in comparison to non-targeted
dendrimers and free pharmaceutical agents when applied in vitro and in vivo15.
10

Exploitation of the FA/FOLRα ligand-receptor relationship has great potential in the
design of targeted therapies; its characterization utilizing the utmost biocompatible,
efficient vectors deserves more attention.

1.7 Hypothesis and Aims of the Current Study
We hypothesize that folate-conjugation to G4 PAMAM dendrimer will enhance dendrimer
specificity and uptake in FOLRα positive tumor cells.
1. Examine the potential of G4FA as vector for intracellular delivery
2. Explore the cellular internalization/ trafficking dynamics of our synthetic vector
3. Evaluate in vitro targeting specificity of folate-conjugated dendrimer

11

2. Materials and Methods
MATERIALS
2.1 Cell culture
HN12 are derived from a lymph node metastasis in a patient with primary squamous cell
carcinoma of the tongue14 . T98A and U87A cells were provided by Dr. Gewirtz’s lab in
Massey Cancer Center at Virginia Commonwealth University (Richmond, VA). U87 cells
are an epithelial-like astrocytoma/glioblastoma cell line classified as a class IV cancer. T98
cells are a fibroblast-like glioblastoma multiforme cell line. Cells were cultured on plastic
culture plates and/or sterile glass cover-slips in Dulbecco’s modified Eagle’s medium
(DMEM, Life Technologies, Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS), 100 units/ml of penicillin, and 100 µg/ml of streptomycin (both from
Thermo Fisher Scientific, Asheville, NC) at 37oC in humid environment with 10% CO2.

2.2 PAMAM Dendrimers
Generation 4.0 polyamidoamine dendrimers were purchased from Dendritech, Inc. Design
(Midland, MI). Engineering and characterization of PAMAM dendrimer derivatives was
performed/provided by Leyuan Xu (responsible for all synthesis and labeling of FAconjugated dendrimer derivatives)
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2.3 Plasmids and Transfection Reagents
EPS8pr-GFP plasmid (pEZX-PF02) purchased from GeneCopoeia (Rockville, MD)
includes an EPS8 promoter region that drives expression of the reporter gene, green
fluorescence protein (GFP). Label IT® Cy3™ Plasmid Delivery Control (red) and TransIT
keratinocyte transfection reagent (referred to as TransIT) were purchased from Mirus Bio
(Madison, WI). Turbofect transfection reageant (referred to as Turbo) was purchased from
Thermo Scientific (Rockford, IL).
2.4 Antibodies
Antibodies that recognize GFP (rabbit mAb #2956P), Rab5 (C8B1, rabbit mAb #3547S),
RCAS1 (rabbit Ab #6960S), and Caveolin-1 (rabbit Ab #3238S) were purchased from Cell
Signaling Technology (Danvers, MA). Dylight-594 Anti-Rabbit IgG antibody (#7074S)
was purchased from Vector Laboratories (Burlingame, CA). Anti-actin (sc-1616) antibody
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish peroxidase
conjugated rabbit anti-goat secondary antibody and HRP-linked anti-rabbit IgG antibody
(#7074S) were purchased from Cell Signaling Technology (Danvers, MA). Western
Lightning ECL was purchased from Perkin Elmer (Waltham, MA). DAPI

2.5 siRNA
esiRNA (endoribonuclease-prepared small interfering RNA) targeting Folate Receptor-α
(siFOLRα), MISSION ® siRNA Universal Negative Control #1 (siNEG), and siRNA
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targeting green fluorescent protein (siGFP), were purchased from Sigma-Aldrich (St.
Louis, MO).

METHODS
2.6 qRT-PCR
Total RNA was extracted using Trizol reagent after washing with cold PBS twice. 3 µg of
total RNA was reverse transcribed (MultiscribeTM Reverse Transcriptase, lot #1207114,
Applied Biosystems, Life Technologies, Grand Island, NY) according to manufacturer’s
protocol. Real-time quantitative PCR was performed using ABI 7500 Fast System
(Applied Biosystems, Rockville, MD) with fluorescence signal detection (SYBR-Green)
after each cycle of amplification as previously described. The calculated cDNA copy
number in each sample was derived from an extrapolated crossing point of a
mathematically derived line extending from the exponential phase of amplification in a
plot of fluorescence intensity (SYBR green) versus cycle number. For each reaction,
diluted amounts of known templates provided quantitative standard curve reactions from
which cDNA copy number could be determined. Tubulin was used as a housekeeping gene
to normalize initial content of total cDNA in the samples. Oligonucleotide primers were
designed using Primerbank database.

2.7 Fluorescence Microscopy:
Fluorescent images were taken using a Zeiss Axiovert 200 inverted fluorescence
microscope (Carl Zeiss Microimaging, Thornwood, NY). Confocal microscopy was
14

performed at the VCU Dept. of Neurobiology & Anatomy Microscopy Facility, supported,
in part, with funding from NIH-NIND Center core grant 5P30NS047463. Confocal images
were taken using a Zeiss LSM 700 confocal laser scanning microscope (Carl Zeiss
Microimaging, Thornwood, NY).

2.8 In vitro Transfection With EPS8pr-GFP plasmid
1x104 cells/well (T98A or U87A) were seeded on sterile, glass coverslips in 12-well plate
and allowed to grow in 1 ml of growth medium containing 10% FBS for 24h. Cells were
transfected via nucleofection (per manufacturer’s protocol) or with the polyplexes of
G4FA/pEPS8pr-GFP (20, 5, 1 µg/1 µg), or TransIT/pEPS8pr-GFP (5 µl/µg) suspended in
100 µl of growth medium containing 1% FBS. After 14h incubation at 37oC and 10% CO2,
the medium in each well was replaced with fresh 1 ml growth medium containing 10%
FBS. Cells were further incubated for 24h and then fixed in cold 100% methanol,
counterstained for DAPI (1:2000 in 1xTBS), mounted in mounting medium (Vectashield,
Vector Laboratories, Burlingame, CA) and studied under fluorescent microscopy.
Separate Transfection for Trypan Blue Assay: 5x104 cells/well were seeded on
sterile, glass coverslips in 12-well plate and allowed to grow in 1 ml of growth
medium containing 10% FBS for 24h. Cells were transfected with the polyplexes of
G4FA/pEPS8pr-GFP (20, 5, 1 µg/1µg) or Turbo/pEPS8pr-GFP (2 µl/1µg)
suspended in 100 µl of growth medium containing 10% FBS. Diluted
dendrimer/DNA mixture was added to each well (or left untreated for negative
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control) rocked, and allowed to incubate at 37o C and 10% CO2 for 48h before
trypan blue assay was conducted.

2.9 Trypan Blue Dye Exclusion Assay
48h post-transfection described above, wells were washed twice with 1xPBS, 300 µl of
0.1% trypsin was added per well and cells were recovered with 200 µl of growth medium.
Cells were spun at 4o for 5 minutes at 13000g. Cell pellets were resuspended in 100 µl of
1xPBS. 50µl of cell suspension was added to 50µl of 0.2% Trypan Blue in triplicate for
each experimental parameter and dye exclusion assay was performed in the Nexcelcom
AutoT4 cell counter according to the manufacturer’s protocol.

2.10 In vitro Intracellular Trafficking Studies:
Co-localization of FITC-labeled Dendrimer With Cellular Organelle Protein Markers
5x104 cells/well were seeded on sterile, glass coverslips in 12 well plate and allowed to
grow in 1 ml of growth medium containing 10% FBS for 24 hours to allow for attachment.
Media was replaced in all wells with 1 ml fresh growth medium 24 hours after seeding.
Experimental wells were incubated with 5 µg of G4FA-FITC in 100 µl of growth medium,
added dropwise for various lengths of time (24 hr, 6h, 3h, 1h, 30 mins), rocked and
incubated at 37o C, 10% CO2 until fixed in cold methanol for 15 minutes, air dried, and
stored -80o C until removed for staining and visualization under fluorescent microscopy.
Immunostaining of Cultured Cells:
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Cells stored at -80o C were washed twice with 1xTBS, and blocked in 1.5% normal
goat serum (or 3% BSA) in TBS for 1 hour, covered, at ambient temperature.
Experimental wells were then incubated with monoclonal anti-Rab5 antibody
(Sigma) diluted 1:200, or anti-RCAS1 (1:800), or anti-CAV1 (1:500) in blocking
buffer overnight at 4oC (negative control wells were left in blocking buffer
overnight). All wells were washed three times with TBS, and incubated with
Dylight 594-conjugated anti-rabbit antibody (1:5000) and DAPI (1:1000) for 1
hour at ambient temperature. Cells were washed four times with TBS, 10 minutes
each on a shaker, and then mounted in Vectashield mounting media (Vector
Laboratories, Burlingame, CA) and imaged using a Zeiss Axiovert 200 microscope.

2.11 In vitro Trafficking of Plasmid DNA Delivered by G4FA
G4FA was labeled with fluorescein isothiocyanate (FITC). T98A cells were seeded on
glass coverslips in 12-well plate at density of 5x104 cells/ well and allowed to grow in 1 ml
of growth medium containing 10% FBS for 24h. Cells were incubated with the polyplexes
of G4FA-FITC/LabelIT ™ Cy3TM plasmid in 20:1 ratio (5µg/0.25 µg in 100 µl of growth
medium) for various lengths of time (30 min, 1h, 3h, 6h, 14h), fixed with cold methanol
for 10 minutes, counterstained with DAPI, and then rinsed with TBS buffer and mounted
for microscopy. Fluorescent images were taken under a Zeiss Axiovert 200 inverted
fluorescence microscope (Carl Zeiss Microimaging, Inc., Thornwood, NY).
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2.12 siRNA-Mediated Knockdown of Folate Receptor-α
2x106 cells were transfected with 1 µg of either siFOLR1 or siNEG using the T-020
program of the Amaxa nucleofector (Amaxa biosystems). Cells were recovered in 20 ml of
growth medium containing 10% FBS and plated into multiple wells: 1 ml/well was added
directly to sterile, glass coverslips in 12-well plate (for treatment with nanovectors and
imaging); and 3ml/ well were added to 6-well plates (for RNA isolation). 24h after
transfection, one 6-well plate was snap frozen at 24h incubation point by aspirating media,
washing in 1xPBS twice, parafilmed, and stored in -80oC until taken out for RNA isolation
24h later. All other wells had media replaced with fresh growth medium containing 10%
FBS and were allowed further incubation for 24 additional hours. 48h after nucleofection,
RNA was isolated and reverse transcribed following manufacturer’s protocol. qRT-PCR
was performed to confirm gene knockdown.

2.13 Challenging Knockdown Cells With G4FA-FITC
48h following transfection with siRNA as described above, media was aspirated from the
12-well plate, and 5 µg of dendrimer (G4FA-FITC) suspended in 1000 µl media was added
per well, rocked, and allowed to incubate at 37o C, 10% CO2 for 1h before fixation in
100% cold methanol. Negative wells were left untreated; media was replaced with fresh 1
ml of growth medium at time of treatment to experimental wells and were fixed in
methanol with experimental wells. Cells were counterstained with DAPI (1:1000 in
1xPBS) for thirty minutes covered at ambient temperature, then washed and mounted on
microscope slides in Vectashield mounting medium (Vector Laboratories, Burlingame,
18

CA). Fluorescent images were taken with Zeiss Axiovert 200 inverted fluorescent
microscope

2.14 G4FA Delivery of siRNA
5x104 cells (T98A-YFP and U87A-YFP) were seeded in 12 well plates, 6 wells included
glass coverslips for subsequent fluorescent imaging while the remaining 6 wells were
seeded for parallel, subsequent protein isolation. Cells were allowed to attach in 1 ml of
growth medium containing 10% FBS for 24 hours. Cells were then treated with polyplexes
of G4FA/siRNA (siYFP or siNEG) in 20:1 ratio (5 µg/0.25 µg) per well, suspended in 100
µl growth medium. Cells were allowed to incubate with polyplexes for 48h before further
experimentation. 48h following transfection, 6 wells were subjected to protein lysis and
Western blot analysis as described below, and the remaining 6 wells were fixed in cold
methanol, counterstained with DAPI, and mounted in Vectashield mounting medium
(Vector Laboratories, Burlingame, CA) for fluorescent microscopy.

2.14.1 Western Blot
After the growth medium was removed, cells were washed twice with cold
PBS, lysed on ice for 10 minutes using 50 µl of cell lysis buffer (20 mM HEPES, pH 7.5,
10 mM EGTA, pH8.0, 40mM β-glycerophosphate, 1% NP-40, 2.5 mM MgCl2, 20 µg/ml
aprotinin, 20 µg/ml leupeptin, 1 mM PMSF), scraped immediately, and transferred to
microcentrifuge tubes. Supernatant was transferred to a fresh tube after 10 min of
microcentrifugation at 10,000 g at 4 °C. Cleared lysates were quantified using Bradford
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assay (BCA; Biorad, Hercules, CA), and equivalent amounts of protein were resolved by
SDS-PAGE and then transferred to polyvinylidene difluoride (PVDF) membrane
(Immobilon-P; Millipore, Billerica, MA). Membrane was blocked in 5% milk in TTBS (10
mM Tris-HCl, pH 7.6, 0.5% Tween-20, 150 mM NaCl) for 1 h at room temperature, and
then incubated in primary antibody diluted (1:10000 for YFP, 1:5000 for actin) in blocking
buffer overnight at 4 °C. After washing in TTBS, bound primary antibodies were detected
using horseradish peroxidase conjugated secondary antibodies and Western Lightning
Enhanced Chemiluminescence (ECL; Perkin-Elmer, Waltham, MA).

20

3. Results and Conclusions
3.1 FOLRα Is Overexpressed In Tumor Cells
FOLRα is considered a highly selective tumor marker due to its frequent overexpression in a variety of tumor types, including carcinomas of the ovaries (>90%),
endometrium, breast, lung, bladder, pancreas, kidney, brain, and neuro-endocrine
carcinomas18,22. As shown in Figure 2, quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) experiments indicate that GBM-derived T98A cells express higher
levels of FOLRα compared to glioblastoma-derived U87A cells, providing suitable
contrast of FOLRα-expressing cell lines for use in our studies. This observation was
confirmed with multiple RNA samples from these cell lines, isolated at different times
from fresh cells. FOLRα overexpression was also evident in HNSCC-derived HN12 cells,
lending support to evidence that FOLRα is frequently overexpressed in a variety of tumor
types.
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Figure 2. qRT-PCR: Folate Receptor Alpha. Folate Receptor-α (FOLRα) screen in
T98A, U87A, HN12 cells. Total RNA was extracted, reverse-transcribed, and qRT-PCR
performed. The relative expression ratio is defined as the expression levels of FOLRα to
that of an internal standard, tubulin. Assays were carried out in triplicate; error bars
represent SEM
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3.2 G4-PAMAM Dendrimer Conjugated To Folic Acid (G4FA) Is An Effective Vector
For Nucleic Acid Delivery
Gene therapy is a proven method for disease prevention and treatment, but efficient
delivery systems are yet to be uncovered. Polyamidoamine (PAMAM) dendrimers readily
form complexes with nucleic acids, including single-stranded oligonucleotides, circular
plasmid DNA, linear RNA, and various sizes of double-stranded DNA23, via electrostatic
interaction between negatively charged phosphates of the nucleic acid and protonated
primary amino groups on the dendrimer surface. A cationic surface charge is imparted to
the complex through high dendrimer-DNA charge ratios, allowing subsequent interaction
with the anionic glycoproteins and phospholipids residing on the cell membrane surface23.
These interactions allow uptake of the DNA-dendrimer complex into the cell cytosol
through passive transport or endocytosis23. The addition of a targeting moiety to
dendrimer, prior to association with nucleic acid, should enhance the uptake of dendrimerDNA complex through receptor-mediated endocytosis. We first wanted to explore the
transfection capabilities of our folate-receptor targeted dendrimer at varying ratios with the
delivery of plasmid DNA.
T98A and U87A cell lines were used to evaluate in vitro gene transfection
efficiency of the folate-conjugated PAMAM dendrimer (G4FA) EPS8pr-GFP plasmid was
delivered with G4FA at varying concentrations for comparison to standard transfection
methods. The transfection efficiency was evaluated in terms of GFP expression,
qualitatively illustrated by fluorescent images and quantified by counting cells expressing
GFP, normalized with respect to the untreated control group. TransIT-keratinocyte
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transfection reagent (referred to as TransIT) is a commercially available transfection
reagent with high efficiency and low toxicity. Transfection of our plasmid induced cellular
GFP expression, driven by the EPS8 gene promoter (epidermal growth factor receptor
kinase substrate 8), which encodes proteins involved in actin cytoskeleton dynamics and
the EGFR pathway. Reporter gene, GFP (enhanced green fluorescent protein), which
fluoresces green when exposed to ultraviolet light, permitted visual confirmation of
successful transfection.
Fluorescent images for each parameter are shown in Figure 3A and 3B for T98A
and U87A cells, respectively. Fluorescence was detectable in all experimental parameters,
excluding the untreated negative control, indicating that our PAMAM dendrimer
conjugated to folic acid (G4FA) is capable of intracellular delivery of nucleic acids within
48 hours. Cytotoxicity was determined by averaging the cell count of multiple fields
(n=10, ~10 cells/field= ~100 cells counted/parameter) for each parameter and relative cell
viability was normalized with respect to the viability of the control group. Figure 3C
indicates that increasing the molar concentration of delivery vector G4FA, with a constant
amount of plasmid DNA, induces increased cell death to the overall cellular population in
both cell lines. Transfection efficiency was quantified by averaging the percentage of cells
expressing GFP, taken from multiple fields representative of the cell population for each
experimental parameter. Our synthetic vector, G4FA, showed efficient transfection at all
concentrations within both cell lines, although its highest concentration, at 20µg, permitted
the highest success (Figure 3D/E).
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Figure 3A: Fluorescent Images Following EPS8pr-GFP Plasmid Transfection T98A.
Analysis of GFP reporter gene expression in T98A cells following transfection with
EPS8pr-GFP plasmid DNA. Cells were cultured on glass coverslips for 24h and
transfected as described in ‘Materials and Methods.’ Cells were fixed in cold methanol,
counterstained with DAPI, and imaged under fluorescent microscopy. All images are
viewed at 400x original magnification
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Figure 3B: Fluorescent Images Following EPS8pr-GFP Plasmid Transfection U87A.
Analysis of GFP reporter gene expression in U87A cells following transfection with
EPS8pr-GFP plasmid DNA. Cells were cultured on glass coverslips for 24h and
transfected as described in ‘Materials and Methods.’ Cells were fixed in cold methanol,
counterstained with DAPI, and imaged under fluorescent microscopy. All images are
viewed at 400x original magnification
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Figure 3C. Cell Viability Following Transfection in T98A and U87A Cells. Cell
viability results in T98A and U87A cells following transfection with EPS8pr-GFP plasmid
DNA via nucleofection (per manufacturer’s protocol) or with the polyplexes of
TransIT/pEPS8pr-GFP (5 µl/µg) or folate conjugated dendrimer (G4-FA)/pEPS8pr-GFP at
varying concentrations (20, 5, 1 µg/1 µg), as described in ‘Materials and Methods’ section.
Control=untreated, Nucleo= nucleofected, TransIT= keratinocyte transfection reagent, 1:1,
5:1, 20:1= G4FA:EPS8pr-GFP (ug). Cytotoxicity was quantified by counting cells in ten
fields per parameter in each cell line. Average cell number for ten fields was calculated and
normalized with respect to the viability (cell number) of the control group. Error bars
represent standard deviation in samples for each cell line.
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Figure 3D. Transfection Efficiency T98A. Transfection efficiency in T98A cells using
folate-conjugated dendrimer (G4FA/pDNA) at varying concentrations (20, 5, 1 µg/1 µg) to
deliver EPS8pr-GFP plasmid DNA as compared to standard transfection methods, as
described in Methods section. Control=untreated, Nucleo= nucleofected, TransIT=
keratinocyte transfection reagent, 1:1, 5:1, 20:1= G4FA:EPS8pr-GFP (ug).
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Figure 3E. Transfection Efficiency U87A. Transfection efficiency in U87A cells using
folate conjugated dendrimer (G4FA/pDNA) at varying concentrations (20, 5, 1 µg/1 µg) to
deliver EPS8pr-GFP plasmid DNA as compared to standard transfection methods
described in the Methods section. Control=untreated, Nucleofection= nucleofected,
TransIT= keratinocyte transfection reagent, 1:1, 5:1, 20:1= G4FA:EPS8pr-GFP (ug).
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3.3 G4FA:EPS8pr-GFP Complex Conveys High Transfection Efficiency With
Limited Cytotoxicity
In vitro transfection implies a trade-off between transfection efficiency and cell
viability. Delivery systems with high transfection efficiency also tend to exert high
cytotoxicity. We wanted to explore cell viability with a universal viability assay following
transfection of cells with folate-conjugated dendrimer complexed with plasmid DNA.
Trypan Blue viability assay is a dye exclusion method that utilizes membrane integrity to
identify dead cells. Dead cells will stain blue because their compromised cellular
membrane allows uptake of the trypan blue dye. These cells are identified by cellometer
software with bright field imaging using Nexcelcom Cellometer AutoT4 Cell counter
(Bioscience LLC, Lawrence, MA).
Trypan blue assay was conducted in triplicate for each experimental parameter
including dendrimer/DNA complexed at varying ratios (20, 5, 1µg/1µg) or turbofection
using turbo/EPS8pr-GFP (2µl/1µg) and negative, untreated control for each cell line.
Results in Figure 4 show a general trend of increased cytotoxicity as dendrimer
concentration is increased, supporting earlier results (Figure 3C) of cell viability with the
same parameters. Taken together with the transfection efficiency results in figures 3D/E, it
is apparent that increased transfection efficiency causes decreased cell viability, but
differences are small when using our synthetic vector. These results demonstrate that our
folate-conjugated dendrimer is a viable approach for efficient delivery of nucleic acids
with limited cytotoxicity, even at higher concentrations.
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Figure 4. Trypan Blue Dye Exclusion Assay. Trypan Blue Dye Exclusion assay results in
T98A and U87A cells following transfection with folate conjugated dendrimer/EPS8prGFP plasmid DNA at varying concentrations (20, 5, 1 µg/1 µg) or Turbo/EPS8pr-GFP
plasmid (2 µl/1µg). Assay was conducted in triplicate for each experimental parameter in
both cell lines, error bars represent standard deviation (n=3).
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3.4 Co-localization of G4FA-FITC With Cellular Organelle Protein Markers
Although dendrimers are widely studied as synthetic delivery systems, their exact
mechanism of internalization and intracellular trafficking is not well understood. We
wanted to track the internalization and trafficking dynamics of our folate-conjugated
dendrimer (G4FA) using fluorescence microscopy. The fluorophore fluorescein
isothiocyanate (FITC) was conjugated to dendrimer surface to facilitate visualization of
our folate-conjugated dendrimer (G4FA-FITC) in these co-localization assays. First, we
treated T98A and U87A cells seeded on cover slips in a 12-well plate with 5 µg G4FAFITC/well, added to separate wells at time points starting at 24h, 6h, 3h, 1h, and 30
minutes before fixation of the whole plate in methanol, 24 hours after the first treatment.
Following fixation, cells were counterstained with DAPI and antibody recognizing the
early endosome protein marker, Rab5, then mounted for fluorescent microscopy (described
in detail in Methods section). Co-localization of G4FA-FITC with Rab5 was apparent at 30
minutes and 1 hour (Fig.5A and 5B) as determined by fluorescent overlap between green
and red channels, and became less obvious at later time points. Figure 5C includes
confocal fluorescent images of the 24h incubation point from this assay in both cell lines.
Figure 5C-1 is a zoom inset of the merged fluorescent confocal image of T98A in Figure
5C. The particular cells in this inset show G4FA-FITC co-localization with early
endosomal marker, Rab5 at various punctate points, indicating its sub-cellular location
within endosome.
We were very interested in further understanding the trafficking dynamics of the
folate-conjugated dendrimer. The experiment was repeated in T98A and U87A cells as
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described in Methods section. Primary antibodies recognizing organelle protein markers
RCAS1 (Golgi) and Caveolin-1 (plasma membrane) permitted fluorescent detection of
respective sub-cellular organelle locations using secondary antibody Dylight-594, to
recognize bound primary antibody. Cells seeded on glass coverslips were treated with 5 ug
of G4FA-FITC per well for indicated incubation times, fixed in cold methanol,
counterstained with DAPI and/or antibodies recognizing cellular organelle protein markers,
and mounted for fluorescent imaging. Images in Figures 5D and 5E are representative of
the results found in T98A and U87A, respectively, using the protein marker for plasma
membrane, Caveolin-1. Co-localization of G4FA-FITC and CAV1 was seen at 3 hour and
6 hour incubation points, indicated by yellow arrowheads. Images in Figure 5F and 5G are
representative of the results found in T98A and U87A, respectively, using protein marker
for Golgi apparatus, RCAS1. Co-localization of G4FA-FITC and RCAS1 was seen
between 1 and 3 hours following addition of dendrimer.
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Figure 5A. Fluorescent Images: T98A Treated with G4FA-FITC, Rab5 Counterstain.
T98A cells treated with G4FA-FITC for various lengths of time before fixation in cold
methanol. Cells were counterstained with DAPI and primary antibody recognizing Rab5
(rabbit), then secondary antibody Dylight-594 (anti-rabbit) for recognition of bound Rab5
primary antibody. Red fluorescence= Rab5, Green= G4FA-FITC, blue= DAPI. Yellow
arrowheads indicate areas of co-localization between FITC-labeled dendrimer and Rab5.
All images are viewed at 630x original magnification.

34

Figure 5B. Fluorescent Images: U87A Treated with G4FA-FITC, Rab5 Counterstain.
U87A cells treated with G4FA-FITC for various lengths of time before fixation in cold
methanol. Cells were counterstained with DAPI and primary antibody recognizing Rab5
(rabbit), then secondary antibody Dylight-594 (anti-rabbit) for recognition of Rab5 bound
primary antibody. Red fluorescence= Rab5, Green= G4FA-FITC, blue= DAPI. Yellow
arrowheads indicate areas of co-localization between FITC-labeled dendrimer and Rab5.
All images are viewed at 630x original magnification.
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Figure 5C. : Confocal Fluorescent Images: T98A/U87A Treated with G4FA-FITC
24h, Rab5 Counterstain. Confocal fluorescent images displaying T98A and U87A cells
treated with G4FA-FITC for 24h. These are the same microscope slides that were imaged
in Figures 4A and 4B, described in Methods section. Individual fluorescent channels
(blue=DAPI, green= G4FA-FITC, Red =Rab5) and merged images are displayed. All
images are viewed at 630x original magnification.

Figure 5C-1. Confocal Fluorescent Image: Inset Zoom T98A. Inset Zoom from the
merged image of T98A above. T98A cells were incubated with G4FA-FITC for 24h, fixed
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in methanol, counterstained with DAPI (blue), primary antibody Rab5, and secondary
antibody Dylight-594 (red) for recognition of bound primary Rab5 antibody. Image is
zoomed from image above viewed at 630x original magnification.

Figure 5D. Fluorescent Images: T98A Treated with G4FA-FITC, CAV1
Counterstain. T98A cells treated with G4FA-FITC for various lengths of time before
fixation in cold methanol. Cells were counterstained with DAPI and primary antibody
recognizing Caveolin-1 (CAV1, rabbit), then secondary antibody Dylight-594 (anti-rabbit)
for recognition of bound CAV1 primary antibody. Red fluorescence= Caveolin-1, Green=
G4FA-FITC, blue= DAPI. Yellow arrowheads indicate areas of co-localization between
FITC-labeled dendrimer and CAV1. All images are viewed at 630x original magnification.
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Figure 5E. Fluorescent Images: U87A Treated with G4FA-FITC, CAV1
Counterstain. U87A cells treated with G4FA-FITC for various lengths of time before
fixation in cold methanol. Cells were counterstained with DAPI and primary antibody
recognizing Caveolin-1 (CAV1, rabbit), then secondary antibody Dylight-594 (anti-rabbit)
for recognition of CAV1 bound primary antibody. Red fluorescence= Caveolin-1, Green=
G4FA-FITC, blue= DAPI. Yellow arrowheads indicate areas of co-localization between
FITC-labeled dendrimer and CAV1. All images are viewed at 630x original magnification.
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Figure 5F. Fluorescent Images: T98A Treated with G4FA-FITC, RCAS1
Counterstain. T98A cells treated with G4FA-FITC for various lengths of time before
fixation in cold methanol. Cells were counterstained with DAPI and primary antibody
recognizing RCAS1 (rabbit), then secondary antibody Dylight-594 (anti-rabbit) for
recognition of bound RCAS1 primary antibody. Red fluorescence= RCAS1, Green=
G4FA-FITC, blue= DAPI. Yellow arrowheads indicate areas of co-localization between
FITC-labeled dendrimer and RCAS1. All images are viewed at 630x original
magnification.
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Figure 5G. Fluorescent Images: U87A Treated with G4FA-FITC, RCAS1
Counterstain. U87A cells treated with G4FA-FITC for various lengths of time before
fixation in cold methanol. Cells were counterstained with DAPI and primary antibody
recognizing RCAS1 (rabbit), then secondary antibody Dylight-594 (anti-rabbit) for
recognition of bound RCAS1 primary antibody. Red fluorescence= RCAS1, Green=
G4FA-FITC, blue= DAPI. Yellow arrowheads indicate areas of co-localization between
FITC-labeled dendrimer and RCAS1. All images are viewed at 630x original
magnification.
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3.5 Dendrimer:Plasmid DNA Complex Dissociation
To understand the trafficking pattern of internalized dendrimer/plasmid polyplexes
in vitro, distribution of the polyplexes in T98A cells at various time points posttransfection was assessed. A cyanine dye-labeled plasmid (Label IT® Cy3TM plasmid) was
employed for in vitro tracking of plasmid. Time course imaging and co-localization results
qualitatively show the co-localization and dissociation of G4FA-FITC/cy3-labeled
plasmid. Figure 6 shows fluorescent images of transfected-T98A cells at time points 30
mins, 1 hour, 3 hours, 6 hours, and 14 hours following addition of polyplexes. Results
show significant co-localization of dendrimer/DNA until after 1 hour following addition of
polyplexes, after which, complexes evidently begin to dissociate.
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Figure 6. Dendrimer:pDNA Dissociation and Intracellular Tracking. Fluorescent
images tracking G4FA-FITC dendrimer/Cy3-labeled pDNA complex dissociation. Cells
were transfected with cy3-labeled plasmid, delivered by the FITC-labeled folateconjugated dendrimer (G4FA-FITC). G4FA-FITC is represented with green fluorescence.
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Red fluorescence detects the cy3-labeled plasmid (i.e., Label IT® Cy3TM plasmid)
delivered by our folate-conjugated dendritic vector. Blue fluorescence detects DAPI
staining of DNA. Individual fluorescent channels are shown at each time point, along with
merged images to display co-localization and dissociation of dendrimer:DNA complexes
within T98A cells. All images are viewed at 1000x original magnification.
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3.6 siRNA-Mediated Down-Regulation of FOLRα
To determine specificity of the folate-conjugated dendrimer for FOLRα, we needed
to test its efficiency in cells whose FOLRα expression was significantly silenced.
Knockdown of folate receptor was performed through nucleofection of T98A cells with
siRNA targeting FOLRα. Negative control cells were nucleofected under the same
conditions, with universal negative control siRNA (Sigma-Aldrich), which has no effect on
gene expression levels. Real-time quantitative polymerase chain reaction results confirmed
successful knockdown of FOLRα in T98A cells 48h post-transfection, with nearly 70%
efficiency, as compared to our control siRNA-treated cells (Figure 7). siFOLRα and
siNEG transfected T98A cells provided contrasting FOLRα -/+ cells, respectively, for
subsequent testing of dendrimer specificity.
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Figure 7. qRT-PCR: Folate Receptor Alpha Knockdown. qRT-PCR results to confirm
knockdown of Folate Receptor-α using siRNA in T98A cells. Total RNA was extracted,
reverse-transcribed, and qRT-PCR performed. The relative expression ratio is defined as
the expression levels of FOLRα to that of an internal standard, Tubulin. Assays were
carried out in triplicate; error bars represent SEM
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3.7 G4FA Is Internalized By Cells In A Receptor-Dependent Manner
To test specificity of the folate-conjugated dendrimer for FOLRα positive tumor
cells, we treated T98A cells from the knockdown experiment described above. siFOLRα
cells and siNEG cells were treated in parallel with (or without in negative control) 5 µg of
G4FA-FITC in 12-well plate. Cells were fixed in cold methanol after 1h incubation then
mounted on microscope slides for study under a fluorescent microscope. As seen in Figure
8, siNEG cells, which are FOLRα-positive, showed significantly increased G4FA-FITC
internalization compared to the siFOLRα cells.
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Figure 8. Fluorescent Images: siFOLRα vs. siNEG Treated With G4FA-FITC.
Fluorescent images showing T98A siFOLR and siNEG cells treated with FITC-labeled
folate-conjugated dendrimer (G4FA-FITC) or no treatment (providing a negative control
for both siRNA parameters). G4FA-FITC is represented with green fluorescence. Blue
fluorescence detects DAPI staining of DNA. Individual fluorescent channels (DAPI, FITC)
and merged images are displayed. All images are viewed at 630x original magnification.
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3.8 G4FA Delivery of siRNA
Nanovectors are studied for delivery of gene therapy, of which there are several
types, including plasmid DNA (pDNA), small interfering RNA (siRNA), small hairpin
RNA (shRNA), microRNA (miRNA), and antisense oligonucleotides.We previously
showed high transfection efficiency of plasmid DNA using the folate-conjugated
dendrimer, and we wanted to explore its capabilities of delivering other gene therapeutics,
like siRNA. siRNA is a potent form of RNA interference that targets specific genes or
mRNA molecules to down regulate gene expression. The process is initiated by
ribonuclease protein, Dicer, which binds to and cleaves dsRNA into fragments, called
small interfering RNAs. Each siRNA is unwound into two strands and the guide strand is
incorporated into the RNA-induced silencing complex (RISC). RISC effectively cleaves
the mRNA, preventing its translation into protein and thus achieving gene silencing24.
The capability of folate-conjugated dendrimer to deliver siRNA was tested by
examining RNA interference-mediated YFP gene knockdown. Stable YFP-expressing cell
lines, T98A-YFP and U87A-YFP were constructed from parental cell lines via
electroporation with YFP plasmid (Amaxa nucleofection, Amaxa Biosystems). YFPexpressing cells were selected for with growth medium supplemented with G418 (1:100).
Prolonged exposure to G418 effectively selected for survival of G418-resistant cells that
had incorporated the YFP plasmid, which includes the neomycin resistance gene (neo). To
exclude any potential interference of FITC, G4FA dendrimers were used without FITC
labeling. siGFP or siNEG was used to transiently transfect YFP-expressing T98A and
U87A cells (T98A-YFP, U87A-YFP). siGFP was used for knockdown of YFP expression
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because YFP, or yellow fluorescent protein, is a designed protein variant of GFP, green
fluorescent protein, and only differs in sequence by one amino acid (Thr 203Tyr
mutation). Therefore, siRNA designed to knockdown GFP expression will also effectively
knockdown YFP expression. From here forward to limit confusion, I will only reference
YFP. Stably transfected cell lines expressing YFP were used to determine transfection
efficiency of the folate-conjugated dendrimer in delivery of siRNA targeting YFP.
Figure 9 shows Western blot analysis of protein lysates 48 hours following
transfection. It is apparent that G4FA/siYFP treated T98A-YFP cells had a significant
knockdown of YFP gene expression after 48 hours. The knockdown of YFP expression in
U87A-YFP cells was less obvious. Figure 10 displays fluorescent images of both cell lines
treated with siNEG or siYFP. Because U87A cells express FOLRα to a lesser extent than
T98A, it would be expected based on our hypothesis, that T98A cells treated in the same
conditions would show enhanced knockdown results when using our folate-conjugated
dendrimer. Therefore, this supports the hypothesis that G4FA confers enhanced uptake in
FOLRα-positive tumor cells.
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Figure 9. Western Blot Analysis of YFP Expression Following siRNA-Mediated
Knockdown. Western blot analysis of total cellular protein lysates prepared from cells
transfected with G4FA-FITC:siRNA (siYFP or siNEG). Total cellular protein lysates were
prepared as described in Methods, and western blotted with indicated antibodies.
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Figure 10. Fluorescent Images of YFP-expressing T98A and U87A Following siRNAMediated Knockdown. Fluorescent images of YFP expressing T98A and U87A cells
treated with either siNEG or siYFP, 48h following transfection with G4FA for delivery of
siRNA. All images are viewed at 630x original magnification.
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4. Discussion
4.1 Exploiting Ligand-Receptor Relationships for Targeted Therapy
Ligand-conjugated nanoparticles have proven useful for tumor-targeted
intracellular delivery through endocytosis-mediated internalization by tumor-specific
receptors. The main objective in the development of targeted therapeutics is to enhance
specific delivery to diseased tissue and reduce off target release. Targeted therapeutics can
be designed to exploit ligand-receptor relationships for enhanced intracellular delivery with
specificity for diseased tissue. Folate receptor-alpha (FOLRα) is considered tumor-specific
due to its frequent overexpression in a variety of tumor types, and negligible expression
levels in normal tissue18. This tumor-specific distribution of FOLRα expression denotes
this receptor as an ideal target for nanovector-based delivery systems in targeted anticancer
therapeutics.
Several research groups have developed nanoparticles conjugated to folate for use
in targeted delivery systems, including metallic nanoparticles, micelles, mesoporous silica,
liposomes, dendrimers, and nanotubes, among others15. Folate conjugates have
successfully delivered imaging and therapeutic agents in malignant cells in both animal
tumor models and human cancer patients, with preferential uptake seen in FOLRα-positive
tumor cells11,15,20. Studies show folate-conjugated delivery systems exert low toxicity and
show increased efficacy and pharmacokinetic behavior in comparison to non-targeted
dendrimers and free pharmaceutical agents when applied in vitro and in vivo15. While there
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is rising interest in research of this ligand-receptor relationship for targeted anticancer
therapeutic delivery systems, studies using polyamidoamine (PAMAM) dendrimers for
this purpose are rather limited. Therefore, our studies were focused on exploring folic acid
conjugation to generation four PAMAM dendrimers for folate receptor-targeted delivery
systems.
qRT-PCR results from glioma cell lines, T98A and U87A, and HNSCC-derived
HN12 cells, confirm frequent FOLRα overexpression in a variety of tumor types (Fig.2).
T98A provided a high-FOLRα expressing cell line for our studies, in contrast with U87A
cells whose expression of FOLRα is markedly lower (Fig. 2). FOLRα overexpression
reflects the tumors’ high demand for folic acid, which is required for continual growth.
Expression of FOLRα is only detectable in tumor cells and normal tissue involved in
embryonic development and folate resorption17. Biodistribution of FOLRα in healthy
tissue is limited to apical surface of polarized epithelia, which is not accessible to
intravenous FOLRα-targeted therapeutics. Exploitation of this ligand-receptor relationship
is a viable approach to enhance specificity of delivery systems for FOLRα-positive
diseased tissue.

4.2 Dendrimer-Based Intracellular Delivery Utilizing Folic Acid Conjugation for
FOLRα-Mediated Endocytosis
Dendrimers are considered the most versatile, compositionally and structurally
controlled nanoscale building blocks12. Their low polydispersity and branched architecture
with numerous surface groups and a hydrophobic core makes their structure ideal for the
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design of highly specialized nanovectors with high loading capacity and multifunctional
capabilities1. The ability to control and tune the chemical structure of dendrimers to design
and engineer highly advanced nanovectors with specific multifunctionality makes their use
exceptional in comparison to other nanovectors. Liposomes, for example, are attractive
vehicles for drug delivery due to their ability to encapsulate large quantities of drug; but
their therapeutic potential is compromised by a trade-off between liposome stability in
circulation and liposome unloading efficiency following cellular internalization11. Another
widely studied nanovector type, polymeric micelles, tend to disassemble below a critical
concentration once diluted in the bloodstream and thereby release drug prematurely before
reaching the target site when tested in vivo25. In comparison to linear polymers, dendrimers
have a much higher loading capacity and their uniform branched structure allows for
controlled and predictable stability and pharmacokinetic behavior. The ability to construct
multifunctional dendrimers allows optimization of nanoparticle pharmacokinetics, delivery
efficiency, stability, biocompatibility, and specific targeting with improved drug and/or
imaging efficacy and reduced toxicity8.
We wanted to explore folate-conjugated dendrimers (G4FA) as a synthetic vector
for specific intracellular delivery. Polyamidoamine (PAMAM) dendrimers are useful for
the delivery of gene therapy because their polycationic surface charge allows electrostatic
interaction with the negatively charged phosphates present in nucleic acids23. Subsequent
interaction of polyplex with anionic phospholipids and glycoproteins present on the cell
membrane becomes possible with high dendrimer:DNA charge ratios, which imparts
overall positive charge to the polyplex. These interactions leading to internalization of
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polyplexes can be optimized with the addition of targeting moieties that induce active
pathways for uptake. Utilizing a ligand that activates tumor-specific receptors induces
receptor-mediated endocytosis of the polyplex, and effectively enhances uptake compared
to passive internalization. Folic acid conjugation to generation four PAMAM dendrimer
provided this ligand-receptor relationship in our studies and we wanted to explore its
efficiency as a delivery system.
T98A and U87A cells were transfected with EPS8pr-GFP plasmid delivered by
G4FA in varying ratios (G4FA:pDNA at 20, 5, 1 µg/1µg) in comparison with proven
standard transfection methods, nucleofection and with TransIT keratinocyte transfection
reagent (Mirus Bio, Madison, WI). Transfection efficiency, determined in terms of GFP
expression, showed a trend of increased efficiency with increased dendrimer:DNA ratio,
supporting the idea that high dendrimer:DNA charge ratios allow more efficient uptake of
polyplexes (Figures 3A, 3B, 3D, 3E). U87A cells displayed GFP expression to a lesser
extent (Fig. 3B) when compared to T98A (Fig. 3A) cells. This may reflect enhanced
uptake of our folate-conjugated dendrimer in FOLRα over expressing cells. This led us to
further studies of dendrimer uptake in FOLRα-positive vs. FOLRα-negative cells,
discussed in detail later.
Figure 3C and Figure 4 show that transfection using our dendrimer has only
minimal effects on cell viability, even with a high dendrimer:DNA ratio. Trypan Blue dye
exclusion assay (Fig. 4), a widely accepted cell viability assay, was included to support
initial cell survival data quantified by cell count and normalized with respect to the
viability of the control group (Fig. 3C). The trade off between cell viability and
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transfection efficiency is less concerning when using low-generation dendrimers because
toxicity of dendrimers is dose-, generation-, and surface-charge-dependent12. As discussed
earlier, the high dendrimer:DNA charge ratio allows for interaction with cell membrane
without exerting excessive toxicity seen with higher generation dendrimers12. The folateconjugated dendrimer proved to be relatively safe for efficient transfection of cells, with
limited cytotoxicity seen only with high concentration of dendrimer.
Effective gene therapy vectors should be safe in terms of immunogenicity and
inflammation while still ensuring intact delivery of DNA/RNA to appropriate cellular
compartments. Expression of our GFP reporter gene in dendrimer-treated cells indicated
that the folate-conjugated dendrimer (G4FA) is a viable approach for intracellular delivery
of nucleic acids, specifically plasmid DNA, within 48 hours. G4FA dendrimer is capable
of entering cells and offloading plasmid DNA, which requires nuclear localization to
replicate and induce gene expression. Although dendrimers are widely studied as delivery
systems, their mechanisms of internalization and intracellular trafficking are not well
understood. We wanted to study how the folate-conjugated dendrimer was trafficked
through the cell after observing its capabilities for nucleic acid delivery within a 48h time
period.

4.3 Internalization and Intracellular Trafficking Dynamics of G4FA
To track the dendrimer’s location in vitro, a fluorescent tag, FITC, was attached to
folate-conjugated dendrimer surface. Cells were treated with G4FA-FITC and
counterstained for subcellular organelle protein markers, including DAPI (DNA), Rab5
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(endosome), RCAS1 (Golgi), and Caveolin-1 (plasma membrane) as described in the
Methods section. Co-localization of G4FA-FITC with endosomal protein marker, Rab5,
within 30 mins and 1 hour supports the idea that our folate-conjugated dendrimer is
internalized via receptor-mediated endocytosis and then shuttled to endosomal
compartments (Figures 5A and 5B). In contrast with other ligand-activated receptormediated endocytosis pathways, folate is essential to proliferative cell vitality, and
therefore, once internalized, it is utilized rather than shuttled to lysosome for degradation.
This cycling is ideal when exploiting a receptor-mediated pathway for internalization of
dendrimer to ensure its stability within cells.
Variability seen with co-localization of G4FA-FITC and other cellular organelle
protein markers, Caveolin-1 and RCAS1, was evident at different time points. Colocalization of G4FA-FITC with CAV1 was evident at 1h, 3h, and 6h following addition of
dendrimer (Figures 5D and 5E). Caveolin-1, is a structural component of
cholesterol/sphingolipid enriched plasma membrane microdomain caveolae, and is
involved in vesicular trafficking, among other functions26. Because we believe G4FAFITC is internalized quickly, within 30 minutes following addition, it is possible that colocalization with CAV1 at later time points represents the uptake of additional folateconjugated dendrimers. Similarly, co-localization of G4FA-FITC with RCAS1, a type III
transmembrane Golgi protein involved in vesicle formation and secretion27, at 1 hour and 3
hours (Figures 5F and 5G) following dendrimer addition, may indicate that our dendrimer
is trafficked to the Golgi following endosomal escape. Further studies are required to better
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understand the trafficking dynamics of folate-conjugated dendrimers following
internalization.

4.4 Dendrimer:DNA Complex Dissociation
Intracellular trafficking of internalized dendrimer nanovectors is not well
understood. We wanted to explore the association and dissociation of dendrimer:plasmid
DNA complex in vitro to better understand trafficking dynamics involved with dendrimer
transfection of plasmid DNA. LabelIT ™ Cy3TM plasmid is a plasmid control with Cy3
labeling to convey fluorescent tracking of plasmid DNA. G4FA-FITC/LabelIT ™ Cy3TM
plasmid in 20:1 ratio (5µg/0.25 µg in 100 µl of growth medium per well) was added to
cells for various lengths of time (30 min, 1h, 3h, 6h, 14h) before fixation in methanol,
counterstaining with DAPI, and mounting for fluorescent microscopy. Co-localization of
G4FA-FITC with cy3 labeled plasmid was evident at early time points (1 h, 3h), after
which, complexes evidently begin to dissociate (Fig. 6). This data supports our hypothesis
that the folate-conjugated dendrimer is internalized rapidly, and once internalized, it is
stable. Dissociation of the dendrimer:DNA complex is important for offloading of
dendrimer cargo, and it would be expected to take time for the complex to traffic through
the cytosol to its intended location before this can occur. Dissociation at later time points
reflects this time lapse, and also lends support to evidence that the folate-conjugated
dendrimer is stable within cells.
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4.5 G4FA Uptake is Enhanced in FOLRα-Positive Tumor Cells
The intention of designing targeted therapeutics is to convey specificity to the
delivery system for a desired site, in this case, tumor cells which express FOLRα. We used
siRNA in the FOLRα-overexpressing cell line, T98A, to knockdown expression of folate
receptor alpha. qRT-PCR results show that nucleofection with siRNA targeting FOLRα
was successful with nearly 70% efficiency, as compared to the control that was transfected
with negative control siRNA (siNEG) (Fig.7). In parallel with seeding cells for RNA
isolation, transfected cells were also plated on coverslips for treatment with dendrimer.
Cells were incubated with 5 µg of G4FA-FITC/well for 1 hour, then fixed in cold
methanol, counterstained for DAPI, and mounted for study under fluorescent microscopy.
Images in Figure 8 display a clear distinction between siFOLRα and siNEG cells treated
with G4FA-FITC. FOLRα positive tumor cells, i.e. siNEG treated T98A cells, show
significantly increased G4FA-FITC internalization compared to siFOLRα cells. (Fig. 8).
These results indicate that our folate-conjugated dendrimer is internalized through
receptor-mediated endocytosis by the FOLRα and this internalization is optimized when
FOLRα is overexpressed. These data supports our hypothesis that folate-conjugation to
dendrimer enhances uptake of dendrimer through FOLRα receptor-dependent mechanism.

4.6 G4FA for siRNA Delivery
Folate-conjugated dendrimer is useful in the delivery of nucleic acids, as shown
previously by our studies with plasmid DNA. We wanted to explore its capabilities to
deliver siRNA, to determine its potential use in siRNA-mediated gene therapy. YFP59

expressing T98A and U87A cells were subjected to transfection using G4FA:siRNA
(either siNEG, a universal negative control, or siYFP) in 20:1 ratio (5 µg/0.25 µg per well),
and were allowed to incubate for 48h before further experimentation was conducted.
Western blot analysis of total cellular protein lysates from both cell lines treated with
siRNA is shown in Figure 9. T98A-YFP cells showed a more efficient knockdown of YFP
expression following transfection with G4FA:siYFP, as compared to U87A-YFP cells.
Because T98A cells have higher expression levels of FOLRα compared to U87A, it would
be expected that the folate-conjugated dendrimer would be more effective at nucleic acid
delivery to T98A cells. Fluorescent images lend support to this data (Fig 10), as
fluorescence of siYFP treated cells is weaker than fluorescence of siNEG treated cells.
Quantification of fluorescent intensity would be beneficial when repeating these
experiments. This experiment shows that G4FA is capable of delivering siRNA, with
higher efficiency in FOLRα positive tumor cells.

4.7 Conclusions and Future Directions
Further research is required to better understand the intracellular trafficking of
dendrimer once it is internalized by cells. It may be useful to explore in vitro colocalization of dendrimer with subcellular organelles in a synchronized cell population in
order to decrease the amount of variability seen with prolonged dendrimer treatment.
Another useful method in co-localization may be to pulse dendrimer treatment, with
subsequent washing to remove treatment. This will effectively exclude the possibility of
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uptake of additional folate-conjugated dendrimers via recycled FOLRα following initial
internalization. This technique will allow intracellular tracking of the dendrimer without
confusion regarding recycling of the receptor and internalization of additional polyplexes.
Understanding the mechanisms of intracellular trafficking of internalized polyplexes will
help researchers design biocompatible nanocarriers capable of site-specific intracellular
delivery.
Folate-conjugated dendrimers have proven useful for tumor-targeted intracellular
delivery through endocytosis-mediated internalization by the tumor-specific receptor,
FOLRα. This could prove useful for the delivery of targeted anticancer therapy in FOLRα
positive tumors. Specificity of therapeutic agents for tumor cells should decrease the
unintended, off-target cytotoxicity that is often associated with standard anticancer
treatment methods. G4FA is capable of efficient intracellular delivery to FOLRα positive
tumor cells and provides a viable approach for tumor-targeted delivery of anticancer
therapeutics, imaging agents, and gene therapy.
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Abbreviations
FOLRα

Folate receptor alpha or FOLR1

FA

Folic acid (folate)

PAMAM

Polyamidoamine

FITC

Fluorescein isothiocyanate

G4

Generation four PAMAM dendrimer

G4FA

Generation four PAMAM dendrimer conjugated to folic acid

G4FA-FITC

Generation four PAMAM dendrimer conjugated to folic acid,
labeled with the fluorophore, FITC

GFP

Green fluorescent protein

YFP

Yellow fluorescent protein

EPS8

Epidermal growth factor receptor pathway substrate 8

EPS8pr-GFP

Plasmid DNA containing EPS8 promoter region to drive
expression of reporter gene, GFP

Cy3

Cyanine-3

LabelIT ® Cy3TM

Cyanine-3 labeled plasmid

pDNA

plasmid DNA

qRT-PCR

Quantitative real-time polymerase chain reaction

siFOLRα

siRNA targeting folate receptor alpha

siNEG

siRNA universal negative control #1

siGFP

siRNA targeting green fluorescent protein

Rab5

Ras-related protein Rab-5
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RCAS1

Receptor binding cancer antigen expressed on SiSo cells

CAV1

Caveolin-1

DAPI

4’, 6-diamidino-2-phenylindole

FBS

Fetal bovine serum

BSA

bovine serum albumin

PBS

Phosphate buffered saline

TBS

Tris-buffered saline

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

EGTA

Ethylene glycol tetraacetic acid

PMSF

Phenylmethylsulfonyl fluoride

SDS-PAGE

Sodium dodecyl sulfate- polyacrylamid gel electrophoresis

TTBS

TBS with Tween®-20

SEM

Standard error of the mean
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